- Home
- CSL vs RPRX Comparison
CSL vs RPRX Comparison
Compare CSL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSL
- RPRX
- Stock Information
- Founded
- CSL 1917
- RPRX 1996
- Country
- CSL United States
- RPRX United States
- Employees
- CSL N/A
- RPRX N/A
- Industry
- CSL Specialty Chemicals
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CSL Industrials
- RPRX Health Care
- Exchange
- CSL Nasdaq
- RPRX Nasdaq
- Market Cap
- CSL 15.9B
- RPRX 15.6B
- IPO Year
- CSL N/A
- RPRX 2020
- Fundamental
- Price
- CSL $381.68
- RPRX $36.34
- Analyst Decision
- CSL Buy
- RPRX Strong Buy
- Analyst Count
- CSL 6
- RPRX 4
- Target Price
- CSL $450.83
- RPRX $46.75
- AVG Volume (30 Days)
- CSL 524.6K
- RPRX 2.9M
- Earning Date
- CSL 07-30-2025
- RPRX 08-06-2025
- Dividend Yield
- CSL 1.05%
- RPRX 2.42%
- EPS Growth
- CSL N/A
- RPRX 54.86
- EPS
- CSL 17.89
- RPRX 2.32
- Revenue
- CSL $5,001,800,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- CSL $5.06
- RPRX $28.60
- Revenue Next Year
- CSL $5.19
- RPRX $8.07
- P/E Ratio
- CSL $21.37
- RPRX $15.64
- Revenue Growth
- CSL 1.37
- RPRX 3.02
- 52 Week Low
- CSL $311.41
- RPRX $24.05
- 52 Week High
- CSL $481.26
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- CSL 48.15
- RPRX 49.03
- Support Level
- CSL $352.62
- RPRX $35.85
- Resistance Level
- CSL $400.14
- RPRX $36.85
- Average True Range (ATR)
- CSL 12.55
- RPRX 0.89
- MACD
- CSL 0.71
- RPRX -0.17
- Stochastic Oscillator
- CSL 43.30
- RPRX 24.59
About CSL Carlisle Companies Incorporated
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.